Journal of Hepatology, Paisant and colleagues
recently presented an interesting and timely study on comparisons between extracellular
contrast agents (ECA) and hepatobiliary contrast agents (HBA) for the diagnosis of
small hepatocellular carcinomas (HCCs), applying imaging criteria from different parts
of the world. The authors should be congratulated for their results, especially as
they performed this multicenter prospective study before the introduction of HBA into
France. Even 10 years after the worldwide use of HBA and the active incorporation
of HBA into the major clinical guidelines,
there remains a surprising paucity of studies comparing ECA and HBA in a head-to-head
manner. The study of Paisant
et al. took a step in the right direction by exploring the impacts of the choice of MRI
contrast agent and diagnostic criteria. However, we would like to highlight some aspects
requiring further consideration.
To read this article in full you will need to make a payment
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
J Hepatol. 2020; 72: 937-945
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
J Hepatol. 2018; 69: 182-236
2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma.
Korean J Radiol. 2019; 20: 1042-1113
Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.
Hepatology. 2018; 68: 723-750
Characterization of 1-to 2-cm liver nodules detected on hcc surveillance ultrasound according to the criteria of the American Association for the Study of Liver Disease: is quadriphasic CT necessary?.
AJR Am J Roentgenol. 2013; 201: 314-321
Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?.
Eur Radiol. 2015; 25: 2859-2868
Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases.
Radiology. 2019; 292: 270
Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?.
Eur Radiol. 2019; 29: 1724-1732
EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice.
Liver Int. 2017; 37: 1515-1525
Use of gadoxetic acid-enhanced liver MRI and mortality in more than 30 000 patients with hepatocellular carcinoma: a nationwide analysis.
Radiology. 2020; 295: 114-124
Published online: June 13, 2020
In Press Journal Pre-Proof
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Access this article on ScienceDirect